SciSparc and Clearmind Medicine Announce International Patent Application for Ibogaine Combo Therapy

SciSparc Ltd., a specialized clinical-stage pharmaceutical company based in Tel Aviv, Israel, has announced a significant milestone in its collaboration with Clearmind Medicine Inc., a biotechnology firm specializing in psychedelic-derived treatments. The collaboration has yielded an international patent application under the Patent Cooperation Treaty for a novel therapeutic combination of Ibogaine and N-Acylethanolamines. This marks a significant step forward in the development of innovative treatments aimed at addressing mental health and addiction issues.

Ibogaine, derived from the root of the Tabernanthe iboga shrub found in Western and Central Africa, has shown promising results in human clinical trials for treating opioid and cocaine use disorders, among other substance dependencies. This makes Ibogaine a potentially valuable anti-addiction agent. Under their collaborative effort, SciSparc and Clearmind are exploring combination therapies that integrate psychedelic molecules with N-acylethanolamines, including Palmitoylethanolamide. To date, Clearmind has filed thirteen patents related to this innovative research with the U.S. Patent and Trademark Office and various other global jurisdictions.

SciSparc Ltd., listed on Nasdaq under the symbol SPRC, focuses on the development of therapies for treating central nervous system disorders and rare diseases. The company is currently involved in several drug development programs based on cannabinoid pharmaceuticals. These programs include SCI-110, aimed at treating Tourette Syndrome and Alzheimer's disease-related agitation, and SCI-210, which targets autism and status epilepticus. In addition to its pharmaceutical endeavors, SciSparc also has a subsidiary that sells hemp seed oil-based products on the Amazon Marketplace.

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to discovering and developing innovative psychedelic-derived treatments to tackle prevalent and underserved health issues, such as alcohol use disorder. The company aims to research and develop these compounds and commercialize them as regulated medicines, foods, or supplements. Clearmind's intellectual portfolio comprises nineteen patent families, including 29 granted patents. The company plans to continue seeking additional patents for its compounds and remains open to acquiring more intellectual property to expand its portfolio. Shares of Clearmind are traded on Nasdaq under the symbol CMND and on the Frankfurt Stock Exchange under the symbol CWY0.